Jian Zhao

Jian Zhao

Auto-generated profile, based on publicly available information

Jian Zhao

Department of Pathology University of Utah Salt Lake City Utah USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
JZJian Zhao
Jian Zhao
NLNicola Longo
Nicola Longo
RLRobert G. Lewis
Robert G. Lewis
TNThomas J. Nicholas
Thomas J. Nicholas
SBSteven E. Boyden
Steven E. Boyden
RMRong Mao
Rong Mao

3 May 2025 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
VTV. Taliercio
V. Taliercio
JZJ. Zhao
J. Zhao
SBS. E. Boyden
S. E. Boyden
RMR. Mao
R. Mao
PBP. Bayrak‐Toydemir
P. Bayrak‐Toydemir
DVD. Viskochil
D. Viskochil
Gorlin‐Goltz Syndrome (GGS) is a rare autosomal dominant genetic disorder encompassing a diverse range of clinical manifestations, including congenital anomalies and predisposition to cancer. Pathogenic variants in PTCH1 and SUFU account for up to 79% and 6% of cases, respectively. Currently, an estimated 15%–27% of individuals with a clinical diagnosis of GGS do not have a pathogenic variant identified in either gene. We report on a 17‐year‐old female referred to the Undiagnosed Disease Network with a clinical diagnosis of GGS that manifested as both classic and unusual findings, including isolated hypogonadotropic hypogonadism and anosmia (Kallmann syndrome), orofacial cleft, and abnormal semicircular canals (SCC). Prior genetic testing, including a targeted gene panel, genomic microarray, exome sequencing, and genome sequencing, was non‐diagnostic, although these studies identified a variant of uncertain significance in CHD7, which may have contributed to elements of the phenotype (e.g., abnormal SCC). Reanalysis of genome sequencing data using research analytic methods, together with karyotyping, FISH, and Sanger sequencing, identified a novel de novo paracentric inversion that truncated PTCH1. These findings underscore the value of in‐depth phenotype‐guided genomic analysis, including chromosomal structural variants, as well as the occurrence of possible dual genetic diagnoses in the same individuals. Moreover, the definitive diagnosis provided the patient and family with a firmer basis for management and counseling.

1 January 2024 in Case Reports in Genetics
Verified
Journal Article
Open access
TWTing Wen
Ting Wen
BSBrian J. Shayota
Brian J. Shayota
LWLauren Wallace
Lauren Wallace
CMCoumarane Mani
Coumarane Mani
NDNeal Davis
Neal Davis
JZJian Zhao
Jian Zhao
Heterozygous microdeletions at 13q12.3 are associated with a rare genetic disorder, 13q12.3 microdeletion syndrome, characterized by intellectual disability, microcephaly, development delay, facial dysmorphisms, atopy, and obesity. Reported 13q12.3 microdeletions vary in size and typically encompass multiple genes. Previous studies have defined a minimal overlap region of 13q12.3 microdeletions and suggested that most of the phenotype associated with the 13q12.3 microdeletion syndrome could be attributed to the loss of the high mobility group box 1 (HMGB1) gene within the overlap region. Here, we report a pediatric patient who had typical phenotypic features of 13q12.3 microdeletion syndrome, including motor and moderate speech developmental delays, microcephaly, and severe atopy, along with anxiety and aggressive behaviors. Trio‐based microarray analysis identified a 62‐kb apparently de novo heterozygous deletion at 13q12.3 in the proband, fully encompassing all coding exons of the HMGB1 gene yet not affecting any other neighboring genes. This case report presents a rare HMGB1 single‐gene deletion in a patient with classic features of 13q12.3 microdeletion syndrome, allowing a better delineation of clinical phenotypes associated with the loss of HMGB1. Our findings, together with previous reports, strongly support the pathogenic role of HMGB1 haploinsufficiency in the 13q12.3 microdeletion syndrome.